DBV Technologies Announces First Participant Screened in THRIVE Phase 2 Study of the VIASKIN® Peanut Patch in Infants ages 6 through 12 Months with Peanut Allergy

▤ Summary

DBV Technologies announced that it has screened the first participant in its THRIVE Phase 2 study of the VIASKIN Peanut Patch for infants ages 6 to 12 months with peanut allergy. The study will test the patch’s safety and efficacy over a long treatment period, with participants wearing the patch daily for 36 months and then entering a follow-up peanut challenge phase. The company says the trial builds on earlier positive results in older children and aims to validate early non-invasive intervention in the youngest patients. This update advances DBV’s clinical pipeline, but it does not announce a commercial product launch or a business transaction.

▦ Linked Companies